Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers
Vishal Goyal(Chandigarh University), Isabela Ribeiro(Drugs for Neglected Diseases Initiative), Carol Ruffell(Gauteng Department of Agriculture and Rural Development), Aljosa Celebic(Luxembourg Institute of Health), Johanna Eriksson, Anouk Neven(Luxembourg Institute of Health), Marylore Chenel, Jean‐Yves Gillon(Drugs for Neglected Diseases Initiative), François Simon(Drugs for Neglected Diseases Initiative), Mathieu Louis(Drugs for Neglected Diseases Initiative), Abhijit Deshmukh(National Institute of Animal Biotechnology), Amit Antarkar, Amaria Saayman(Clinvet), Nabila Ibnou Zekri Lassout(Drugs for Neglected Diseases Initiative), Stephen Robinson(Drugs for Neglected Diseases Initiative), Henri Caplain(Drugs for Neglected Diseases Initiative), S Victor(Clinvet), Edrich Krantz(Clinvet)
Cited by 4
Related Papers
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis
|BMC Public Health|2017|72